Moreover, on the basis of intratumoral heterogeneity, a phase II prospective trial was conducted and discovered that the KRAS WT CRC patients who responded and then progressed during a cetuximab-based therapy received a further line of therapy without cetuximab could restore KRAS WT clones, which could constitute the major part of the tumor mass again. This evidence concerns the gene KRAS and neoplasm.